Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Meisel

Neurology Atlanta, GA Medical Doctor

NPI 1679513865 CMS profile 724398

1579 Monroe Dr Ne Ste F, Ste F 602, Atlanta, GA 30324

Open in the dashboard

General payments

$7,465

410 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Meisel of Atlanta, GA is reported in the CMS Open Payments database as having received $7,465 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,770 83
2024 General $1,487 74
2023 General $915 49
2022 General $906 48
2021 General $799 51
2020 General $733 47
2019 General $854 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Meisel
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jeremy Meisel were reported at $1,770. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jeremy Meisel Neurology median Middle half National median
2019 $854 $474 $118–$2,177 $163
2020 $733 $367 $82–$2,309 $114
2021 $799 $438 $104–$2,547 $132
2022 $906 $442 $103–$2,388 $149
2023 $915 $464 $119–$2,312 $160
2024 $1,487 $468 $119–$2,323 $164
2025 $1,770 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $981 71 payments
  2. Pfizer Inc. $567 32 payments
  3. Supernus Pharmaceuticals, Inc. $495 34 payments
  4. Harmony Biosciences LLC $428 15 payments
  5. Jazz Pharmaceuticals Inc. $418 19 payments
  6. Teva Pharmaceuticals USA, Inc. $373 18 payments
  7. Biogen, Inc. $327 19 payments
  8. Lilly USA, LLC $287 16 payments
  9. SK Life Science, Inc. $260 14 payments
  10. Lundbeck LLC $257 11 payments
  11. Other $3,072 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,341 407 payments
  2. Education $124 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $733 57 payments
  2. QULIPTA $602 39 payments
  3. NURTEC ODT $567 32 payments
  4. ZAVZPRET $505 29 payments
  5. OXTELLAR XR $272 21 payments
  6. APTIOM $254 13 payments
  7. TROKENDI XR $252 14 payments
  8. EMGALITY $230 13 payments
  9. Austedo XR $227 10 payments
  10. TYSABRI $208 13 payments
  11. Other $4,637 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

4,474

Median for Neurology: 833

Drug cost

$375,339

Median for Neurology: $202,670

Branded share of claims

16.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 12 $68,861
Nurtec Odt Rimegepant Sulfate Brand 33 $54,506
Keppra Xr Levetiracetam Brand 14 $29,479
Qulipta Atogepant Brand 23 $28,284
Ubrelvy Ubrogepant Brand 19 $26,666
Ajovy Syringe Fremanezumab-Vfrm Brand 17 $19,477
Emgality Pen Galcanezumab-Gnlm Brand 18 $17,104
Trokendi Xr Topiramate Brand 12 $15,377
Aimovig Autoinjector Erenumab-Aooe Brand 19 $13,985
Oxcarbazepine Generic 274 $12,894

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$231,982

Medicare's payments for the services billed

Medicare patients

251

Average age 72

Services billed

1,792

136 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 34%
Depression 31%
Ischemic heart disease 29%
Chronic kidney disease 28%
Alzheimer's or dementia 23%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $167
$167 — —
UBRELVY
  • AbbVie, Inc. $136
$136 19 —
Leqembi
  • Eisai Inc. $106
  • Biogen, Inc. $23
$129 — —
QULIPTA
  • AbbVie, Inc. $120
$120 23 —
NURTEC ODT
  • PFIZER INC. $117
$117 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record